{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:59:35Z","timestamp":1792486775810,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2008]]},"DOI":"10.1016\/j.ctrv.2008.03.007","type":"journal-article","created":{"date-parts":[[2008,6,3]],"date-time":"2008-06-03T11:45:33Z","timestamp":1212493533000},"page":"S3-S18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":202,"special_numbering":"S1","title":["Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group"],"prefix":"10.1016","volume":"34","author":[{"given":"David M.","family":"Reid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Doughty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Heys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene V.","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Selby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2008.03.007_bib1","unstructured":"Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement. 2000;17:1\u201345."},{"key":"10.1016\/j.ctrv.2008.03.007_bib2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.7326\/0003-4819-115-11-837","article-title":"Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group","volume":"115","author":"Seeley","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ctrv.2008.03.007_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/jbmr.5650100202","article-title":"How many women have osteoporosis now?","volume":"10","author":"Melton","year":"1995","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2008.03.007_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/oxfordjournals.aje.a008920","article-title":"Risk factors for osteoporotic fractures: a summary of the literature and statistical synthesis","volume":"144","author":"Nguyen","year":"1996","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib5","first-page":"S1","article-title":"The prevention of falls in later life","volume":"34","author":"Gibson","year":"1987","journal-title":"Dan Med Bull"},{"key":"10.1016\/j.ctrv.2008.03.007_bib6","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S8756-3282(09)80004-5","article-title":"Epidemiology of osteoporosis","volume":"13","author":"Kanis","year":"1992","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2008.03.007_bib7","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/00003086-199510000-00028","article-title":"Determinants of reduced survival following hip fractures in men","volume":"319","author":"Poor","year":"1995","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ctrv.2008.03.007_bib8","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1359\/jbmr.2003.18.6.1139","article-title":"Adverse outcomes of osteoporotic fractures in the general population","volume":"18","author":"Melton","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2008.03.007_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jbmr.5650070214","article-title":"The incidence of clinically diagnosed vertebral fracture: a population-based study in Rochester, Minnesota","volume":"7","author":"Cooper","year":"1992","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2008.03.007_bib10","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/BF01623689","article-title":"The hospital burden of vertebral fracture. A study of national register sources","volume":"7","author":"Johnell","year":"1997","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.ctrv.2008.03.007_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/archinte.160.1.77","article-title":"Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures, Fracture Intervention Trial Research Group","volume":"160","author":"Nevitt","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ctrv.2008.03.007_bib12","unstructured":"World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group. WHO Technical Report Series No. 843, Geneva, World Health Organization; 1994. p. 1\u2013129."},{"key":"10.1016\/j.ctrv.2008.03.007_bib13","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1001\/archinte.1991.00400100100017","article-title":"A model of lifetime osteoporosis impact","volume":"151","author":"Chrischilles","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ctrv.2008.03.007_bib14","first-page":"27","article-title":"Functional recovery after fractures of the distal forearm. Analysis of radiographic and other factors affecting the outcome","volume":"77","author":"Kaukonen","year":"1988","journal-title":"Ann Chir Gynaecol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib15","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0002-9343(05)80039-7","article-title":"The patient with fracture: the risk of subsequent fractures","volume":"98","author":"Silman","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.ctrv.2008.03.007_bib16","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","article-title":"Risk of new vertebral fracture in the year following a fracture","volume":"285","author":"Lindsay","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2008.03.007_bib17","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/BF01622200","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group","volume":"4","author":"Kanis","year":"1994","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.ctrv.2008.03.007_bib18","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","article-title":"The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women","volume":"18","author":"Kanis","year":"2007","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.ctrv.2008.03.007_bib19","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00198-003-1508-y","article-title":"Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)","volume":"14","author":"Fogelman","year":"2003","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.ctrv.2008.03.007_bib20","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1200\/JCO.2004.08.148","article-title":"Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy","volume":"22","author":"Sverrisdottir","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib21","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","article-title":"Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group","volume":"25","author":"Gnant","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib22","unstructured":"Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Bone mineral density (BMD) at 5 years after diagnosis in premenopausal patients with endocrine-responsive breast cancer, after 3 years of adjuvant endocrine treatment with goserelin and tamoxifen or anastrozole or both treatments in combination with zoledronic acid \u2013 new results from ABCSG-12. Breast Cancer Res Treat 2007;106(Suppl 1):Abstract 26."},{"key":"10.1016\/j.ctrv.2008.03.007_bib23","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00198-004-1780-5","article-title":"Assessment of fracture risk","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.ctrv.2008.03.007_bib24","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","article-title":"Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/00002018-200528050-00004","article-title":"Chemotherapy-induced ovarian failure: manifestations and management","volume":"28","author":"Molina","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.ctrv.2008.03.007_bib26","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1093\/annonc\/3.suppl_4.S105","article-title":"Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP\/ABVD chemotherapy for Hodgkin\u2019s disease","volume":"3","author":"Kreuser","year":"1992","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1365-2265.1998.00550.x","article-title":"Bone mineral density in women with cytotoxic-induced ovarian failure","volume":"49","author":"Howell","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ctrv.2008.03.007_bib28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/hon.2900100308","article-title":"Bone mineral density (BMD) in patients with lymphoma: the effects of chemotherapy, intermittent corticosteroids and premature menopause","volume":"10","author":"Ratcliffe","year":"1992","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/07357909809039747","article-title":"Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy","volume":"16","author":"Headley","year":"1998","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ctrv.2008.03.007_bib30","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","article-title":"Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer","volume":"19","author":"Shapiro","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10549-004-2625-9","article-title":"Baseline bone mineral density of the total lumbar spine may predict for chemotherapy-induced ovarian failure","volume":"90","author":"Shapiro","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2008.03.007_bib32","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","article-title":"Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients","volume":"15","author":"Saarto","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib33","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","article-title":"Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study","volume":"15","author":"Delmas","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1210\/jc.2006-1272","article-title":"Prevention of bone loss in survivors of breast cancer: a randomized, double-blind, placebo-controlled clinical trial","volume":"92","author":"Greenspan","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2008.03.007_bib35","first-page":"11","article-title":"Effects of estrogen deficiency in women castrated when young","volume":"106","author":"Svanberg","year":"1981","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ctrv.2008.03.007_bib36","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/0895-4356(96)00211-9","article-title":"Fracture risk following bilateral oophorectomy","volume":"49","author":"Melton","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib37","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(80)92592-1","article-title":"Prevention of spinal osteoporosis in oophorectomised women","volume":"2","author":"Lindsay","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2008.03.007_bib38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00042192-199906040-00006","article-title":"Long-term compliance with estrogen replacement therapy in surgical postmenopausal women: benefits to bone and analysis of factors associated with discontinuation","volume":"6","author":"Castelo-Branco","year":"1999","journal-title":"Menopause"},{"key":"10.1016\/j.ctrv.2008.03.007_bib39","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1034\/j.1600-0412.1999.780611.x","article-title":"Compliance to estrogen treatment one to three years after hysterectomy and bilateral salpingoophorectomy. The cohorts lifestyle, knowledge of ERT, benefits etc","volume":"78","author":"Hee","year":"1999","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ctrv.2008.03.007_bib40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0020-7292(97)00272-5","article-title":"Effect of long-term hormone replacement therapy on the bone in ovariectomized women with cancer","volume":"60","author":"Kurabayashi","year":"1998","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.ctrv.2008.03.007_bib41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0020-7292(94)90356-5","article-title":"Effect of hormone replacement therapy on bone and lipid metabolism in women oophorectomized for the treatment of gynaecologic malignancies","volume":"47","author":"Yasuda","year":"1994","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ctrv.2008.03.007_bib42","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000071532","article-title":"Long-term effects of hormone replacement therapy on bone mineral density in girls oophorectomized in adolescence","volume":"55","author":"Kanaoka","year":"2003","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.ctrv.2008.03.007_bib43","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group E. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687\u2013717.","DOI":"10.1016\/S0140-6736(05)66544-0"},{"key":"10.1016\/j.ctrv.2008.03.007_bib44","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib45","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.2005.02.3515","article-title":"Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status","volume":"24","author":"Vehmanen","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib46","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0002-9343(99)80251-4","article-title":"The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women","volume":"99","author":"Grey","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.ctrv.2008.03.007_bib47","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/028418698430007","article-title":"Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer","volume":"37","author":"Resch","year":"1998","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib48","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1210\/jcem.83.4.4688","article-title":"Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients","volume":"83","author":"Marttunen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2008.03.007_bib49","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.1994.12.5.992","article-title":"Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study","volume":"12","author":"Kristensen","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0169-6009(08)80220-6","article-title":"Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women","volume":"22","author":"Ward","year":"1993","journal-title":"Bone Miner"},{"key":"10.1016\/j.ctrv.2008.03.007_bib51","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","article-title":"Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer","volume":"326","author":"Love","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2008.03.007_bib52","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/030089169608200114","article-title":"Effects of one-year adjuvant treatment with tamoxifen on bone mineral density in postmenopausal breast cancer women","volume":"82","author":"Barni","year":"1996","journal-title":"Tumori"},{"key":"10.1016\/j.ctrv.2008.03.007_bib53","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF01806497","article-title":"Elemental composition of bone minerals in women with breast cancer treated with adjuvant amoxifen","volume":"37","author":"Kalef-Ezra","year":"1996","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2008.03.007_bib54","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1210\/jcem.87.8.8750","article-title":"Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial","volume":"87","author":"Delmas","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2008.03.007_bib55","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1210\/jc.2002-020396","article-title":"Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women","volume":"87","author":"Rogers","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2008.03.007_bib56","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJM199809103391104","article-title":"Endogenous hormones and the risk of hip and vertebral fractures among older women, Study of Osteoporotic Fractures Research Group","volume":"339","author":"Cummings","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2008.03.007_bib57","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1359\/jbmr.2000.15.9.1835","article-title":"Serum estradiol and sex hormone-binding globulin and the risk of hip fracture in elderly women: the EPIDOS study","volume":"15","author":"Chapurlat","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2008.03.007_bib58","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2008.03.007_bib59","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Thurlimann","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2008.03.007_bib60","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","article-title":"Survival and safety of exemestane versus tamoxifen after 2\u20133 years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial","volume":"369","author":"Coombes","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2008.03.007_bib61","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Benefits of switching postmenoausal women with hormone sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2008.03.007_bib62","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2008.03.007_bib63","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.2005.09.121","article-title":"ASCO Technology assessment on aromatase inhibitors for early breast cancer","volume":"23","author":"Winer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib64","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Forbes","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib65","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","article-title":"Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)","volume":"21","author":"Eastell","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2008.03.007_bib66","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the ATAC Trial (18233230)","volume":"26","author":"Eastell","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib67","first-page":"614","article-title":"Effects of the aromatase inhibitor letrozole in healthy postmenopausal women: rationale for prevention","volume":"11","author":"Harper-Wynne","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ctrv.2008.03.007_bib68","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98","volume":"25","author":"Coates","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib69","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","article-title":"Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA 17","volume":"24","author":"Perez","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib70","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1158\/1078-0432.CCR-04-0438","article-title":"Effects of the steroidal aromatase inhibitor exemestane and the non-steroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats","volume":"10","author":"Goss","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2008.03.007_bib71","first-page":"3485","article-title":"Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetate","volume":"23","author":"Martinetti","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2008.03.007_bib72","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.ejca.2007.08.029","article-title":"Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy post menopausal women","volume":"43","author":"McCloskey","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2008.03.007_bib73","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/j.ejca.2006.07.005","article-title":"Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study","volume":"42","author":"Geisler","year":"2006","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2008.03.007_bib74","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1200\/jco.2006.24.18_suppl.554","article-title":"Vitamin D deficiency: a threat to bone health in breast cancer patients during adjuvant treatment with aromatase inhibitors","volume":"24","author":"Lonning","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib75","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study","volume":"8","author":"Coleman","year":"2007","journal-title":"Lancet Oncol"},{"issue":"l","key":"10.1016\/j.ctrv.2008.03.007_bib76","first-page":"502","article-title":"The SABRE (Study of Anastrozole with the Bisphosphonate RisEdronate) study: 12 month analysis","volume":"106","author":"Van Poznak","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"18S","key":"10.1016\/j.ctrv.2008.03.007_bib77","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1200\/jco.2007.25.18_suppl.553","article-title":"Effect of monthly oral ibandronate on anastrozole-induced bone loss during adjuvant treatment for breast cancer one-year results from the ARIBON study","volume":"25","author":"Lester","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib78","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2008.03.007_bib79","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/cncr.23259","article-title":"Zoledronic acid in the prevention of cancer treatment induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer","volume":"112","author":"Bundred","year":"2008","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2008.03.007_bib80","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1007\/s001980070007","article-title":"Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs","volume":"11","author":"Delmas","year":"2000","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.ctrv.2008.03.007_bib81","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2008.03.007_bib82","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1007\/s001980070004","article-title":"Preanalytical variability of biochemical markers of bone turnover","volume":"11","author":"Hannon","year":"2000","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.ctrv.2008.03.007_bib83","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1056\/NEJM199803123381107","article-title":"Treatment of postmenopausal osteoporosis","volume":"338","author":"Eastell","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2008.03.007_bib84","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737208000510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737208000510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:18:17Z","timestamp":1759655897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737208000510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":84,"alternative-id":["S0305737208000510"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2008.03.007","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2008]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2008.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}